Currently, there are 17.32M common shares owned by the public and among those 8.15M shares have been available to trade.
The company’s stock has a 5-day price change of -11.22% and -61.06% over the past three months. BNOX shares are trading -82.90% year to date (YTD), with the 12-month market performance down to -80.38% lower. It has a 12-month low price of $0.18 and touched a high of $1.60 over the same period. BNOX has an average intraday trading volume of 9.59 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -10.99%, -11.67%, and -61.32% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Bionomics Ltd. ADR (NASDAQ: BNOX) shares accounts for 14.45% of the company’s 17.32M shares outstanding.
It has a market capitalization of $4.38M and a beta (3y monthly) value of 0.30. The earnings-per-share (ttm) stands at -$0.94. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.01% over the week and 12.53% over the month.
Earnings per share for the fiscal year are expected to increase by 65.83%, and 31.58% over the next financial year.
Looking at the support for the BNOX, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on September 28, 2023, with the firm’s price target at $8. Maxim Group coverage for the Bionomics Ltd. ADR (BNOX) stock in a research note released on September 28, 2023 offered a Buy rating with a price target of $10. H.C. Wainwright was of a view on January 10, 2022 that the stock is Buy, while Evercore ISI gave the stock Outperform rating on January 10, 2022, issuing a price target of $17. Cantor Fitzgerald on their part issued Overweight rating on January 10, 2022.
